Search results for: 'biological industry'

In 2024, the life science (LS) industry s focus on precision health will intensify. LS companies will augment their omics-based research capabilities and increasingly deploy AI and bioinformatics to discover personalized therapies. Partnerships between pharmaceutical companies and technology vendors will multiply, to support innovation in drug disc...

This study focuses on the top 10 strategic imperatives impacting the MedTech industry in 2025. The industry includes the medical devices and medical imaging and informatics markets. Top transformations impacting industry growth include competitive intensity, compression of the value chain, industry convergence, transformative megatrends, internal...

This market insight provides data for the Global Opioid Therapeutics market. The analysis looks at opioid pharmaceutical pipeline drugs currently in the market and drugs that are in Phase III stage, which pose a potential threat to competitors. It also offers a competitive analysis of the drugs, and the forecast outcome and impact of each of these ...

The global pharmaceutical market is projected to reach approximately $1.72 trillion in 2026, with large molecules driving most incremental growth while small molecules remain the sector’s cash flow base. The current growth cycle concentrates on cardiometabolic and oncology, led by GLP-1 platforms and antibody–drug conjugates (ADCs). Competitive adv...

The study on the "Global Biologics Contract Development & Manufacturing Organizations (CDMO) Market: Companies-to-Action" presents an overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies towa...

24 Jul 2020  |  North America  |  Market Research

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

Infographics

×

Key Issues Addressed

With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, r...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) highlights recent advances in biological therapies such as RNA therapies, biosimilars, gene therapies and cell therapies for the management of diseases such as cancer, neurodegenerative disorders and rare diseases. The research also provides technological insigh...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

This research service covers the U.S. rheumatoid arthritis (RA) market from 2007 to 2017, with 2010 as the base year. Included in this research service are products currently in the market, products in development, and patient forecasts. Market challenges, drivers, and restraints are identified and assessed. Strategic recommendations are presented ...